Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03715933 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03715933 · ClinicalTrials.gov record · last posted 2026-05-22

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Name: Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas — clinical trial record (NCT03715933)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1

SponsorInhibrx Biosciences, Inc

Started2018-10-08

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This is a first-in-human, open-label, non-randomized, three-part phase 1 trial of INBRX-109, which is a recombinant humanized tetravalent antibody targeting the human death receptor 5 (DR5).

Protocol amendment history 4 changes detected by DataLookout

2026-05-23

Enrollment increased: 321 → 411 participants

2026-05-23

Trial arms changed: 11 → 14

2026-05-23

Primary completion pushed: 2026-06 → 2028-12

2026-05-23

Completion pushed: 2026-12 → 2029-06

Trial Details

NCT Number	NCT03715933
Lead Sponsor	Inhibrx Biosciences, Inc
Conditions	Ewing Sarcoma, Colorectal Adenocarcinoma
Enrollment	411 participants
Start Date	2018-10-08
Primary Completion	2028-12 (estimated)
Study Completion	2029-06 (estimated)
Updated on ClinicalTrials.gov	2026-05-22